Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.55 |
| ▸ | DPP4 | P27487 | 3/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23844240 | 0.79 | HRH3 (0.44) | NOTUMMAPTSMN1; SMN2LMNAALOX12 | |
| SCHEMBL24681307 | 0.79 | NOTUM (0.37) | NOTUMDPP4 | |
| SCHEMBL26684538 | 0.78 | HRH4 (0.45) | — | |
| SCHEMBL3057878 | 0.77 | NOTUM (0.54) | NOTUMDPP4ADRB1MAPTSMN1; SMN2 | |
| SCHEMBL19368254 | 0.76 | NOTUM (0.51) | NOTUMDPP4MAPTSMN1; SMN2LMNA | |
| SCHEMBL14275554 | 0.76 | NOTUM (0.59) | NOTUMDPP4ADRB1MAPTSMN1; SMN2 | |
| SCHEMBL17025296 | 0.76 | AR (0.68) | NOTUMDPP4ADRB1MAPTSMN1; SMN2 | |
| SCHEMBL23844510 | 0.75 | NOTUM (0.50) | NOTUMDPP4L3MBTL1MAPK1 | |
| SCHEMBL2056318 | 0.75 | ADRB1 (0.58) | NOTUMDPP4ADRB1MAPTSMN1; SMN2 | |
| SCHEMBL29157655 | 0.75 | NOTUM (0.45) | NOTUMDPP4ADRB1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH INC (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2022115879-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | DPYD, TP53, GLS | NOTUM 1416/4885DPP4 1366/4885ADRB1 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.